ArticleClinical ophthalmology (Auckland, N.Z.)2026
A Comparison of the Efficacy and Safety of Modified Baerveldt Drainage Implants versus Ahmed Glaucoma Valves After 1 Year of Follow-Up.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: A modification to the Baerveldt Glaucoma Implant allows for earlier postoperative intraocular pressure (IOP) reduction. The goal of this study was to evaluate the efficacy and safety of this modification (vsBGI) compared to the Ahmed Glaucoma Valve (AGV) out to 1 year of follow-up. Patients and Methods: This retrospective cohort study included 124 eyes from patients aged ≥18 years with glaucoma who underwent implantation of vsBGIs or AGVs. Longitudinal outcomes were analyzed using adjusted linear mixed-effects models to account for baseline differences. Kaplan-Meier survival curves were used to compare surgical success. The primary outcomes were IOP and number of medications. Results: A total of 124 eyes were included (62 AGV and 62 vsBGI). Preoperative IOP was found to be significantly higher in the AGV group prior to surgery. At 1 year, median IOP reduction was similar between groups. Kaplan-Meier analysis showed no significant between-group difference under the liberal (≤21 mmHg), conservative (≤14 mmHg), or individualized target-IOP criteria, whereas the vsBGI group showed higher survival probability at the intermediate threshold criterion (≤17 mmHg). The vsBGI group required significantly fewer medications on Day 1. No statistically significant differences in postoperative complication frequency or type were observed between groups. Conclusion: The vsBGI showed broadly comparable 1-year efficacy and safety to the AGV, with similar IOP reduction and surgical survival, fewer early postoperative medications, and comparable visual acuity and adverse event rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.